Table 6 Comparative investigations of the possibility to substitute paclitaxel with other drugs
Study | Treatment arms | FIGO stage | n | PFS (m) | OS(m) | p |
|---|---|---|---|---|---|---|
SCOTROC-1 | Â | III-IV | Â | Â | Â | 0.71 |
| Â | Carboplatin (AUC5)+Paclitaxel (175 mg/mq) | Â | 539 | 14.8 | N.A | Â |
| Â | Carboplatin (AUC5)+Docetaxel (75 mg/mq) | Â | 538 | 15.0 | N.A | Â |
MITO-2 | Â | IC-IV | Â | Â | Â | N.S. |
| Â | Carboplatin (AUC5) + Paclitaxel (175 mg/mq) | Â | 410 | 16.8 | 53.2 | Â |
| Â | Carboplatin (AUC5) + Liposomal doxorubicin (30 mg/mq) | Â | 410 | 19.0 | 61.6 | Â |